CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.
chimeric antigen receptor
immunotherapy
natural killer cells
solid tumors
tumor-associated antigens
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
03
2021
accepted:
14
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
The tumor microenvironment (TME) is greatly multifaceted and immune escape is an imperative attribute of tumors fostering tumor progression and metastasis. Based on reports, the restricted achievement attained by T cell immunotherapy reflects the prominence of emerging other innovative immunotherapeutics, in particular, natural killer (NK) cells-based treatments. Human NK cells act as the foremost innate immune effector cells against tumors and are vastly heterogeneous in the TME. Currently, there exists a rapidly evolving interest in the progress of chimeric antigen receptor (CAR)-engineered NK cells for tumor immunotherapy. CAR-NK cells superiorities over CAR-T cells in terms of better safety (e.g., absence or minimal cytokine release syndrome (CRS) and graft-versus-host disease (GVHD), engaging various mechanisms for stimulating cytotoxic function, and high feasibility for 'off-the-shelf' manufacturing. These effector cells could be modified to target various antigens, improve proliferation and persistence
Identifiants
pubmed: 34178661
doi: 10.3389/fonc.2021.673276
pmc: PMC8223062
doi:
Types de publication
Journal Article
Review
Retracted Publication
Langues
eng
Pagination
673276Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2021 Marofi, Al-Awad, Sulaiman Rahman, Markov, Abdelbasset, Ivanovna Enina, Mahmoodi, Hassanzadeh, Yazdanifar, Stanley Chartrand and Jarahian.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 2020 May 6;122:200-206
pubmed: 32388482
Cancer Immunol Immunother. 2017 Apr;66(4):537-548
pubmed: 28184969
Hum Immunol. 2012 Mar;73(3):248-57
pubmed: 22234167
Clin Immunol. 2017 Apr;177:3-11
pubmed: 26883680
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
J Immunol. 2004 Nov 15;173(10):6072-81
pubmed: 15528343
Pediatr Hematol Oncol. 2017 Aug;34(5):320-330
pubmed: 29039999
PLoS One. 2011;6(6):e20740
pubmed: 21698239
Mol Ther. 2019 Jun 5;27(6):1114-1125
pubmed: 30962163
Cancers (Basel). 2019 Dec 27;12(1):
pubmed: 31892230
Mol Cancer Ther. 2020 Apr;19(4):988-998
pubmed: 32241872
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6
pubmed: 18987320
Crit Care Med. 2017 Feb;45(2):e124-e131
pubmed: 27632680
Oncotarget. 2017 Aug 2;8(39):66137-66153
pubmed: 29029499
Oncogene. 2021 Jan;40(4):717-730
pubmed: 33262461
Acta Pharmacol Sin. 2015 Oct;36(10):1191-9
pubmed: 26073325
Mol Ther. 2018 Feb 7;26(2):366-378
pubmed: 29339014
J Transl Med. 2015 Aug 25;13:277
pubmed: 26303618
Cancers (Basel). 2019 Mar 15;11(3):
pubmed: 30875953
PLoS One. 2014 Jan 29;9(1):e87086
pubmed: 24489840
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Cancer Discov. 2019 Oct;9(10):1422-1437
pubmed: 31340937
Front Immunol. 2017 Mar 23;8:329
pubmed: 28386260
Leuk Lymphoma. 2012 May;53(5):958-65
pubmed: 22023526
J Biol Chem. 2009 May 22;284(21):14136-46
pubmed: 19307177
Biol Blood Marrow Transplant. 1996 May;2(2):68-75
pubmed: 9118301
Immunity. 2008 Apr;28(4):571-80
pubmed: 18394936
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Retrovirology. 2013 Nov 01;10:127
pubmed: 24182203
Hum Gene Ther. 2012 Oct;23(10):1090-100
pubmed: 22779406
Cell Prolif. 2020 Aug;53(8):e12858
pubmed: 32592435
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
J Immunol Res. 2017;2017:6915912
pubmed: 29423418
Mol Ther Oncolytics. 2019 Dec 24;16:75-85
pubmed: 31970285
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
J Immunother. 2015 Jan;38(1):24-36
pubmed: 25415285
Oncol Rep. 2015 Jan;33(1):95-102
pubmed: 25333815
Cancer Immunol Res. 2019 Mar;7(3):363-375
pubmed: 30651290
Oncology. 2001;61 Suppl 2:1-13
pubmed: 11694782
J Virol. 1993 Oct;67(10):5911-21
pubmed: 8371349
Immunity. 1998 Jun;8(6):693-701
pubmed: 9655483
Immunol Rev. 2002 Oct;188:147-54
pubmed: 12445288
J Immunother Cancer. 2018 Dec 4;6(1):136
pubmed: 30514403
J Hematol Oncol. 2020 Dec 7;13(1):168
pubmed: 33287875
Biomed Res Int. 2018 Feb 25;2018:1812535
pubmed: 29682521
Cancer Immunol Immunother. 2016 Apr;65(4):477-84
pubmed: 26810567
Cancer Res. 2016 Mar 15;76(6):1578-90
pubmed: 26979791
Blood. 2012 Jan 12;119(2):399-410
pubmed: 22096237
Annu Rev Immunol. 1996;14:619-48
pubmed: 8717527
J Hematol Oncol. 2019 May 16;12(1):49
pubmed: 31097020
Oncol Rep. 2017 Jun;37(6):3189-3200
pubmed: 28440503
Lung Cancer. 2002 Jan;35(1):23-8
pubmed: 11750709
Cancers (Basel). 2019 Feb 06;11(2):
pubmed: 30736355
Cancer. 1997 Jun 15;79(12):2320-8
pubmed: 9191519
Oncoimmunology. 2015 Dec 21;5(4):e1119354
pubmed: 27141401
Front Immunol. 2020 May 08;11:873
pubmed: 32457760
J Immunother. 2015 Jun;38(5):197-210
pubmed: 25962108
Sci Rep. 2019 Dec 10;9(1):18729
pubmed: 31822751
Elife. 2020 Jul 07;9:
pubmed: 32633234
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
Semin Cancer Biol. 2018 Dec;53:178-188
pubmed: 30081230
J Immunol Methods. 2005 Jan;296(1-2):31-6
pubmed: 15680148
Surgery. 2019 Oct;166(4):503-508
pubmed: 31416604
J Immunogenet. 1986 Apr-Jun;13(2-3):141-51
pubmed: 3493296
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Oncotarget. 2016 May 10;7(19):27764-77
pubmed: 27050072
Cell Stem Cell. 2018 Aug 2;23(2):160-161
pubmed: 30075127
Nat Rev Drug Discov. 2010 May;9(5):360-1
pubmed: 20431565
Cells. 2020 Jul 22;9(8):
pubmed: 32707982
Cancer Sci. 2020 May;111(5):1478-1490
pubmed: 32133731
Hum Gene Ther. 2017 Oct;28(10):886-896
pubmed: 28836469
Cancer Res. 2013 Mar 15;73(6):1892-9
pubmed: 23302230
Sci Rep. 2018 Apr 18;8(1):6220
pubmed: 29670256
Front Pharmacol. 2015 Feb 12;6:21
pubmed: 25729364
Nat Rev Genet. 2014 Aug;15(8):541-55
pubmed: 25022906
Front Pharmacol. 2020 Jul 30;11:1089
pubmed: 32848731
Cancer Immunol Immunother. 2018 Apr;67(4):575-587
pubmed: 29299659
Biochem Soc Trans. 2013 Feb 1;41(1):245-51
pubmed: 23356291
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397
pubmed: 29209143
Int J Cancer. 1975 Aug 15;16(2):216-29
pubmed: 50294
Bull Cancer. 2019 Nov;106(11):946-958
pubmed: 31711572
Front Immunol. 2020 Jun 23;11:1295
pubmed: 32714324
Nat Protoc. 2020 Aug;15(8):2705-2727
pubmed: 32681154
Oncology. 2018;95(5):288-296
pubmed: 30138925
Int J Mol Sci. 2019 Feb 03;20(3):
pubmed: 30717444
Immunogenetics. 2017 Aug;69(8-9):567-579
pubmed: 28695291
Front Immunol. 2019 Dec 06;10:2836
pubmed: 31867006
Blood. 2005 Jul 1;106(1):376-83
pubmed: 15755898
Eur Radiol. 2005 Jan;15(1):4-13
pubmed: 15616814
Front Immunol. 2017 May 18;8:533
pubmed: 28572802
Cancers (Basel). 2018 Dec 18;10(12):
pubmed: 30567306
PLoS One. 2018 Jan 17;13(1):e0191358
pubmed: 29342200
Zhonghua Yi Xue Za Zhi. 2018 Mar 20;98(11):860-866
pubmed: 29609271
Curr Top Microbiol Immunol. 1992;158:1-24
pubmed: 1582242
J Cancer Res Ther. 2020;16(2):393-396
pubmed: 32474529
Acta Pharmacol Sin. 2018 Feb;39(2):167-176
pubmed: 28880014
Front Immunol. 2020 Jan 21;10:3038
pubmed: 32038612
Med Sci Monit. 2021 Jan 27;27:e927464
pubmed: 33500378
Front Immunol. 2018 Feb 14;9:267
pubmed: 29491867
Curr Gene Ther. 2004 Dec;4(4):357-72
pubmed: 15578987
BMC Immunol. 2018 Aug 3;19(1):27
pubmed: 30075754
Am J Cancer Res. 2018 Jun 01;8(6):1083-1089
pubmed: 30034945
Gynecol Oncol. 2020 Jun;157(3):810-816
pubmed: 32268953
Mol Ther. 2015 Feb;23(2):330-8
pubmed: 25373520
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
Front Immunol. 2021 Jan 07;11:611163
pubmed: 33488617
Cold Spring Harb Protoc. 2020 Apr 1;2020(4):098079
pubmed: 32238593
Int Immunopharmacol. 2019 Sep;74:105695
pubmed: 31254958
J Hematol Oncol. 2020 Jun 12;13(1):76
pubmed: 32532329
J Neurooncol. 2014 Jan;116(1):31-9
pubmed: 24062140
Blood. 2014 Oct 9;124(15):2370-9
pubmed: 25185262
Stem Cell Reports. 2017 Dec 12;9(6):1796-1812
pubmed: 29173894
Blood. 2002 Aug 15;100(4):1265-73
pubmed: 12149207
Sci Rep. 2020 Feb 18;10(1):2815
pubmed: 32071339
J Immunol Res. 2018 Oct 15;2018:4263520
pubmed: 30410941
Reproduction. 2017 Dec;154(6):815-825
pubmed: 28971893
Nat Commun. 2020 Sep 23;11(1):4810
pubmed: 32968061
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
Mol Med Rep. 2019 Sep;20(3):2823-2831
pubmed: 31524233
Oncoimmunology. 2016 Oct 28;6(1):e1250050
pubmed: 28197367
Cancer Res. 2003 May 15;63(10):2470-6
pubmed: 12750268
Blood. 2007 Oct 1;110(7):2561-4
pubmed: 17475906
Cancer Immunol Immunother. 2015 May;64(5):621-34
pubmed: 25711293
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Blood. 2017 Oct 19;130(16):1857-1868
pubmed: 28835441
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
J Natl Cancer Inst. 2015 Dec 06;108(5):
pubmed: 26640245
Biochem Biophys Res Commun. 2020 Mar 26;524(1):96-102
pubmed: 31980173
Immun Inflamm Dis. 2017 Dec;5(4):493-502
pubmed: 28695716
Cytometry A. 2020 Sep;97(9):891-899
pubmed: 32198974
Int J Surg Oncol. 2012;2012:834852
pubmed: 22312544
Anticancer Res. 2018 Sep;38(9):5049-5056
pubmed: 30194149
Nat Immunol. 2020 Aug;21(8):835-847
pubmed: 32690952
J Immunother. 2019 Oct;42(8):284-296
pubmed: 31261167
Cell Stem Cell. 2018 Aug 02;23(2):181-192.e5
pubmed: 30082067
J Immunol Res. 2018 Sep 3;2018:6248590
pubmed: 30255106
Cancer Immunol Immunother. 2012 Sep;61(9):1451-61
pubmed: 22310931
Semin Cancer Biol. 2002 Feb;12(1):3-13
pubmed: 11926409
J Immunol. 2007 Apr 1;178(7):4011-6
pubmed: 17371953
J Exp Med. 1990 Mar 1;171(3):695-714
pubmed: 2137855
Nat Immunol. 2014 May;15(5):431-8
pubmed: 24658051
Eur J Haematol. 2003 Jul;71(1):29-38
pubmed: 12801296
J Immunol. 2013 Aug 1;191(3):1486-95
pubmed: 23817426
Cancer Immunol Res. 2018 Dec;6(12):1548-1560
pubmed: 30282672
Nat Biotechnol. 2020 Feb;38(2):233-244
pubmed: 31907405
Afr Health Sci. 2020 Jun;20(2):822-832
pubmed: 33163049
Clin Cancer Res. 2011 Nov 1;17(21):6671-80
pubmed: 21908576
Immunotherapy. 2017 Jan;9(2):123-130
pubmed: 28128714
Sci Rep. 2015 Jul 09;5:11483
pubmed: 26155832
Trends Mol Med. 2012 Jul;18(7):377-84
pubmed: 22613370
Neuro Oncol. 2017 Oct 19;19(11):1425-1426
pubmed: 29059447
J Cell Mol Med. 2012 Mar;16(3):569-81
pubmed: 21595822